title: Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: a meta-analysis.
abstract: BACKGROUND
  Neoadjuvant chemotherapy (NAC) before surgery has already shown the therapy effectiveness inpatients with cervical cancer. The present meta-analysis was conducted to determine whether the response to NAC predicts for prognosis.
  
  
  METHODS
  Systematic computerized searches of the Pub-Med and Web of Knowledge were performed. Prognosis outcomes included progression-free survival (PFS), and overall survival (OS). The pooled odd ratio (OR) was estimated by using fixed-effect model or random-effect model according to heterogeneity between studies.
  
  
  RESULTS
  Eighteen studies with 1,785 patients were included. Cisplatin-based NAC treatments were most commonly used. The clinical response rate ranged from 48.4 to 93.0 %, and the pathological response rate ranged from 27.6 to 30.6 %. The pooled ORs estimating the association of PFS with NAC response were 5.707 (95 % CI3.564–9.137), 6.798 (95 % CI 4.716–9.799), 6.327 (95 %CI 4.398–9.102), and 5.214 (95 % CI 3.748–7.253) at 1-,2-, 3-, and 5-year follow-up, respectively, and the pooled ORs estimating the association of OS with NAC response were 6.179 (95 % CI 3.390–11.264), 9.155 (95 % CI5.759–14.555), 8.431 (95 % CI 5.667–12.543), and 5.785(95 % CI 4.124–8.115) at 1-, 2-, 3-, and 5-year follow-up,respectively. No obvious statistical heterogeneity was detected. Funnel plots and Egger’s tests did not reveal publication bias. Sensitivity analysis showed the results of meta-analysis were robust.
  
  
  CONCLUSIONS
  This meta-analysis confirms that response to NAC is an indicator for PFS and OS, and suggests that patients-achieving response of NAC before surgery predicts favorable prognosis for cervical cancer patients.
authors.forename: Qing
authors.initials: Q
authors.lastname: Ye
authors.forename: Hong-Xin
authors.initials: HX
authors.lastname: Yuan
authors.forename: Hong-Lin
authors.initials: HL
authors.lastname: Chen
mesh_terms: D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D011379:Prognosis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000601:surgery*
references.citation: Eur J Cancer. 2003 Nov;39(17):2470-86
references.pmid: 14602133
references.citation: Gynecol Oncol. 2008 Sep;110(3):308-15
references.pmid: 18606439
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Int J Gynecol Cancer. 2010 Nov;20(8):1399-404
references.pmid: 21051984
references.citation: Int J Gynecol Cancer. 2009 Apr;19(3):417-22
references.pmid: 19407570
references.citation: BMJ. 2003 Sep 6;327(7414):557-60
references.pmid: 12958120
references.citation: Gynecol Oncol. 2011 Feb;120(2):275-9
references.pmid: 21093896
references.citation: Int J Gynecol Cancer. 2009 Jul;19(5):943-7
references.pmid: 19574789
references.citation: Anticancer Res. 2010 Sep;30(9):3731-5
references.pmid: 20944162
references.citation: BMC Cancer. 2008 Oct 11;8:295
references.pmid: 18847499
references.citation: J Obstet Gynaecol Res. 2006 Jun;32(3):315-23
references.pmid: 16764623
references.citation: Int J Gynecol Cancer. 2006 Mar-Apr;16(2):631-7
references.pmid: 16681738
references.citation: Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S100-9
references.pmid: 22999501
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4137-45
references.pmid: 15961761
references.citation: Int J Gynaecol Obstet. 2012 Apr;117(1):23-6
references.pmid: 22265255
references.citation: Int J Gynecol Cancer. 2010 May;20(4):611-6
references.pmid: 20686381
references.citation: Australas Radiol. 2001 Nov;45(4):491-5
references.pmid: 11903183
references.citation: Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S36-40
references.pmid: 18586309
references.citation: Gynecol Oncol. 2011 Oct;123(1):99-104
references.pmid: 21741694
references.citation: Gynecol Oncol. 2013 Mar;128(3):524-9
references.pmid: 23146686
references.citation: Eur J Cancer. 2012 Oct;48(15):2353-60
references.pmid: 22503395
references.citation: Expert Opin Pharmacother. 2011 Feb;12(2):165-73
references.pmid: 21226631
references.citation: Cochrane Database Syst Rev. 2012 Dec 12;12:CD007406
references.pmid: 23235641
references.citation: Gynecol Oncol. 2013 Jan;128(1):49-53
references.pmid: 23063763
references.citation: Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S187-91
references.pmid: 16185756
references.citation: J Formos Med Assoc. 2002 Mar;101(3):195-202
references.pmid: 12051015
references.citation: Cancer Chemother Pharmacol. 2013 Mar;71(3):657-62
references.pmid: 23263187